Research Group Inherited Cancer (RGIC)

Publications 2026

Bancroft EK, Page EC, McHugh J, Thomas S, Taylor N, Pope J, Evans DG, Rothwell J, Grindedal EM, Maehle L, James P, McKinley J, Mascarenhas L, Side L, Thomas T, van Leerdam ME, van Asperen CJ, Kiemeney LALM, Ringelberg J, Vlaming M, Rønlund K, Osther PJS, Helfand BT, Hutten CG, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Salinas M et al. (2026)
Targeted Prostate Cancer Screening in Carriers of BRCA1 or BRCA2 Pathogenic Germline Variants Detects Clinically Relevant Disease: 5-year Results from the IMPACT Study
Eur Urol, 89 (5), 457-468
DOI 10.1016/j.eururo.2026.01.031, PubMed 41714267

Hovda T, Sober S, Padrik P, Kruuv-Kao K, Grindedal EM, Vamre TBA, Eikeland E, Hofvind S, Sahlberg KK (2026)
A clinical pilot study for personalized risk-based breast cancer screening utilizing a polygenic risk score
PLoS One, 21 (7), e0345431
DOI 10.1371/journal.pone.0345431, PubMed 42418475

Lin HY, Sarkar I, Mazumder H, Huang PY, Muir KR, Schleutker J, Pashayan N, Batra J, Neal DE, Grönberg H, Nielsen SF, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Travis RC, Stanford JL, Mucci LA, Kibel AS, Cussenot O, Berndt SI, Koutros S, Sørensen KD, Cybulski C, Grindedal EM, Hoegel J, Maier C, Hamilton RJ, Rosenstein BS et al. (2026)
Polygenic risk score with KLK3 SNP-SNP interaction pairs for predicting prostate cancer aggressiveness
Commun Med (Lond), 6 (1)
DOI 10.1038/s43856-026-01645-z, PubMed 42204244

Ullern H, Johannessen JA, Kasikci F, Formica M, Karimi Melve N, Andresen S, Brech A, Axcrona K, Jørgensen K, Farkas L, Enserink JM, Knævelsrud H (2026)
FLCN loss is characterized by SQSTM1/p62 accumulation despite functional autophagy flux in Birt-Hogg-Dubé syndrome-associated kidney cancer
Autophagy Rep, 5 (1), 2705631
DOI 10.1080/27694127.2026.2705631, PubMed 42569319

Vassy JL, Dornisch AM, Karunamuni R, Gatzen M, Kachulis CJ, Lennon NJ, Brunette CA, Danowski ME, Hauger RL, Garraway IP, Kibel AS, Lee KM, Lynch JA, Maxwell KN, Ratner D, Rose BS, Teerlink CC, Xu GJ, Hofherr SE, Lafferty KA, Larkin K, Malolepsza E, Patterson CJ, Toledo DM, Donovan JL, Hamdy FC, Martin RM, Neal DE, Turner EL, Andreassen OA et al. (2026)
Genomic risk model to implement precision prostate cancer screening in clinical care: the ProGRESS study
Nat Cancer, 7 (2), 352-367
DOI 10.1038/s43018-025-01103-0, PubMed 41588240

Publications 2025

Grindedal EM, Zucknick M, Hovland ST, Grimsrud TK, Mæhle L (2025)
A prospective observational study of pancreatic cancer risk in men and women with pathogenic variants in BRCA1 or BRCA2
BJC Rep, 3 (1), 83
DOI 10.1038/s44276-025-00199-2, PubMed 41387549

Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Jong MM, Links TP, Brems H, Aerden M, Brunet J, Lleuger-Pujol R, Hüneburg R, Aretz S, Colas C, Villy MC, Woodward ER, Evans DG, Bosch DGM, Donze SH, Foretová L, Blatnik A, Leter EM, Tischkowitz M, Jahn A, de Putter R, Dupont J, Briskemyr S, Steinke-Lange V, Baldassarri M, Anastasiadou VC, Irmejs A, Oliveira C et al. (2025)
The risk of a second primary cancer in PTEN Hamartoma Tumor Syndrome (PHTS)
Genet Med, 27 (10), 101467
DOI 10.1016/j.gim.2025.101467, PubMed 40433764

Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, de Putter R, Brems H, Van Daele SH, Anastasiadou VC, Foretová L, Benusiglio PR, Gerasimenko A, Colas C, Villy MC, Houdayer C, Branchaud M, Hüneburg R, Aretz S, Jahn A, Steinke-Lange V, Innella G, Turchetti D, Barili V, Genuardi M, Panfili A, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Donze SH et al. (2025)
Cancer prognosis and treatment results in patients with PTEN Hamartoma Tumour Syndrome (PHTS)-a European cohort study
BJC Rep, 3 (1), 42
DOI 10.1038/s44276-025-00157-y, PubMed 40468016

Hyldebrandt HK, Stormorken AT, Vitelli V, Geirdal AØ, Grindedal EM (2025)
Experiences with risk-reducing mastectomy in Norwegian BRCA1/2 carriers without prior breast cancer
Fam Cancer, 24 (3), 60
DOI 10.1007/s10689-025-00484-6, PubMed 40728683

Lucas AL, Simeone DM, Katona BW, Paiella S, Zogopoulos G, Sears RC, Grindedal EM, Wadlow RC, Borazanci E, Gordon OK, Kastrinos F, Trevino JG, Kupfer SS, Park WG, Everett JN, Kureshi NM, DeMuth G, Ford L, King T, Palma NA, Brand RE (2025)
Validation of a Serum-Based Biomarker Signature for Detection of Early-Stage Pancreatic Ductal Adenocarcinoma
Gastroenterology, 170 (2), 375-384
DOI 10.1053/j.gastro.2025.08.034, PubMed 41143761

Publications 2024

Bjørnstad PM, Aaløkken R, Åsheim J, Sundaram AYM, Felde CN, Østby GH, Dalland M, Sjursen W, Carrizosa C, Vigeland MD, Sorte HS, Sheng Y, Ariansen SL, Grindedal EM, Gilfillan GD (2024)
Publisher Correction: A 39 kb structural variant causing Lynch syndrome detected by optical genome mapping and nanopore sequencing
Eur J Hum Genet, 32 (5), 601-602
DOI 10.1038/s41431-023-01519-1, PubMed 38172175

Grindedal EM, Zucknick M, Stormorken A, Rønne E, Tandstad NM, Isaacs WB, Axcrona K, Mæhle L (2024)
Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome
Prostate, 84 (10), 945-953
DOI 10.1002/pros.24711, PubMed 38629217

Hendricks LAJ, Verbeek KCJ, Schuurs-Hoeijmakers JHM, Mensenkamp AR, Brems H, de Putter R, Anastasiadou VC, Villy MC, Jahn A, Steinke-Lange V, Baldassarri M, Irmejs A, de Jong MM, Links TP, Leter EM, Bosch DGM, Høberg-Vetti H, Tveit Haavind M, Jørgensen K, Mæhle L, Blatnik A, Brunet J, Darder E, Tham E, Hoogerbrugge N, Vos JR (2024)
Lifestyle Factors and Breast Cancer in Females with PTEN Hamartoma Tumor Syndrome (PHTS)
Cancers (Basel), 16 (5)
DOI 10.3390/cancers16050953, PubMed 38473316

Hyldebrandt HK, Grindedal EM, Huppertz-Hauss G, Vitelli V, Johansen N, Stormorken AT (2024)
The impact of hysterectomy on subsequent colonoscopy in women with Lynch Syndrome
Scand J Gastroenterol, 59 (8), 1015-1020
DOI 10.1080/00365521.2024.2366969, PubMed 38946231

Hyldebrandt HK, Stormorken AT, Vitelli V, Mæhle L, Schlichting E, Grindedal EM (2024)
Risk reducing mastectomy in Norwegian BRCA1/2 carriers
Eur J Surg Oncol, 51 (3), 109571
DOI 10.1016/j.ejso.2024.109571, PubMed 39765192

Sjursen W, Hyldebrandt HK, Lavik LAS, Haukanes BI, Ariansen S, Briskemyr S, Sylvander AE, Haavind MT, Olsen MF, Røyset ES, Vetti H, Stormorken A, Grindedal EM (2024)
PMS2 mutation spectra in Norway and risk of cancer for carriers of pathogenic variants
Hered Cancer Clin Pract, 22 (1), 20
DOI 10.1186/s13053-024-00292-6, PubMed 39334433

Srinivasan S, Kryza T, Bock N, Tse BWC, Sokolowski KA, Janaththani P, Fernando A, Moya L, Stephens C, Dong Y, Röhl J, Alinezhad S, Vela I, Perry-Keene JL, Buzacott K, Nica R, IMPACT Study, Gago-Dominguez M, PROFILE Study Steering Committee, Schleutker J, Maier C, Muir K, Tangen CM, Gronberg H, Pashayan N, Albanes D, Wolk A, Stanford JL, Berndt SI, Mucci LA et al. (2024)
A PSA SNP associates with cellular function and clinical outcome in men with prostate cancer
Nat Commun, 15 (1), 9587
DOI 10.1038/s41467-024-52472-6, PubMed 39505858

Publications 2023

Bjørnstad PM, Aaløkken R, Åsheim J, Sundaram AYM, Felde CN, Østby GH, Dalland M, Sjursen W, Carrizosa C, Vigeland MD, Sorte HS, Sheng Y, Ariansen SL, Grindedal EM, Gilfillan GD (2023)
A 39 kb structural variant causing Lynch Syndrome detected by optical genome mapping and nanopore sequencing
Eur J Hum Genet, 32 (5), 513-520
DOI 10.1038/s41431-023-01494-7, PubMed 38030917

Darst BF, Shen J, Madduri RK, Rodriguez AA, Xiao Y, Sheng X, Saunders EJ, Dadaev T, Brook MN, Hoffmann TJ, Muir K, Wan P, Le Marchand L, Wilkens L, Wang Y, Schleutker J, MacInnis RJ, Cybulski C, Neal DE, Nordestgaard BG, Nielsen SF, Batra J, Clements JA, Cancer BioResource AP, Grönberg H, Pashayan N, Travis RC, Park JY, Albanes D, Weinstein S et al. (2023)
Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry
Am J Hum Genet, 110 (7), 1200-1206
DOI 10.1016/j.ajhg.2023.05.010, PubMed 37311464

Roht L, Hyldebrandt HK, Stormorken AT, Nordgarden H, Sijmons RH, Bos DK, Riegert-Johnson D, Mantia-Macklin S, Ilves P, Muru K, Wojcik MH, Kahre T, Õunap K (2023)
AXIN2-related oligodontia-colorectal cancer syndrome with cleft palate as a possible new feature
Mol Genet Genomic Med, 11 (6), e2157
DOI 10.1002/mgg3.2157, PubMed 36860143

Wang A, Shen J, Rodriguez AA, Saunders EJ, Chen F, Janivara R, Darst BF, Sheng X, Xu Y, Chou AJ, Benlloch S, Dadaev T, Brook MN, Plym A, Sahimi A, Hoffman TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Laisk T, Figuerêdo J, Muir K, Ito S, Liu X, Biobank Japan Project, Uchio Y, Kubo M, Kamatani Y, Lophatananon A et al. (2023)
Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants
Nat Genet, 55 (12), 2065-2074
DOI 10.1038/s41588-023-01534-4, PubMed 37945903

Publications 2022

Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LA, West CML, Nielsen SF, Kibel AS, Cussenot O, Berndt SI et al. (2022)
Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score
Prostate Cancer Prostatic Dis, 25 (4), 755-761
DOI 10.1038/s41391-022-00497-7, PubMed 35152271

Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM (2022)
"It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing
Hered Cancer Clin Pract, 20 (1), 6
DOI 10.1186/s13053-022-00212-6, PubMed 35123550

Publications 2021

Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley J, Mascarenhas L, Syngal S, Ukaegbu C, Side L, Thomas T et al. (2021)
A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study
Lancet Oncol, 22 (11), 1618-1631
DOI 10.1016/S1470-2045(21)00522-2, PubMed 34678156

Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG et al. (2021)
Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Nat Genet, 53 (1), 65-75
DOI 10.1038/s41588-020-00748-0, PubMed 33398198

Conti DV, Darst BF, Moss LC, Saunders EJ, Sheng X, Chou A, Schumacher FR, Olama AAA, Benlloch S, Dadaev T, Brook MN, Sahimi A, Hoffmann TJ, Takahashi A, Matsuda K, Momozawa Y, Fujita M, Muir K, Lophatananon A, Wan P, Le Marchand L, Wilkens LR, Stevens VL, Gapstur SM, Carter BD, Schleutker J, Tammela TLJ, Sipeky C, Auvinen A, Giles GG et al. (2021)
Publisher Correction: Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction
Nat Genet, 53 (3), 413
DOI 10.1038/s41588-021-00786-2, PubMed 33473200

Huynh-Le MP, Fan CC, Karunamuni R, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir K, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Donovan JL, Hamdy FC, Martin RM, Nielsen SF, Nordestgaard BG, Wiklund F, Tangen CM, Giles GG, Wolk A, Albanes D, Travis RC, Blot WJ, Zheng W, Sanderson M, Stanford JL, Mucci LA, West CML et al. (2021)
Polygenic hazard score is associated with prostate cancer in multi-ethnic populations
Nat Commun, 12 (1), 1236
DOI 10.1038/s41467-021-21287-0, PubMed 33623038

Karunamuni RA, Huynh-Le MP, Fan CC, Thompson W, Eeles RA, Kote-Jarai Z, Muir K, Lophatananon A, UKGPCS collaborators, Schleutker J, Pashayan N, Batra J, APCB BioResource (Australian Prostate Cancer BioResource), Grönberg H, Walsh EI, Turner EL, Lane A, Martin RM, Neal DE, Donovan JL, Hamdy FC, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA et al. (2021)
Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer
Prostate Cancer Prostatic Dis, 24 (2), 532-541
DOI 10.1038/s41391-020-00311-2, PubMed 33420416

Siglen E, Vetti HH, Lunde ABF, Hatlebrekke TA, Strømsvik N, Hamang A, Hovland ST, Rettberg JW, Steen VM, Bjorvatn C (2021)
Ask Rosa - The making of a digital genetic conversation tool, a chatbot, about hereditary breast and ovarian cancer
Patient Educ Couns, 105 (6), 1488-1494
DOI 10.1016/j.pec.2021.09.027, PubMed 34649750

Publications 2020

Berger I, Berland S, Rodriguez JR, Aamodt H, Sitek JC, Jørgensen K, Johansen TEB (2020)
[Birt-Hogg-Dubé syndrome]
Tidsskr Nor Laegeforen, 140 (6)
DOI 10.4045/tidsskr.18.0848, PubMed 32321218

Berger I, Aamodt H, Jorgensen K, Berland S, Sitek JC, Johansen TEB, Rodriguez JR (2020)
Birt-Hogg-Dube-syndrome
Tidsskr. Nor. Laegeforen., 140 (6), 565-569

Brandão A, Paulo P, Maia S, Pinheiro M, Peixoto A, Cardoso M, Silva MP, Santos C, Eeles RA, Kote-Jarai Z, Muir K, Ukgpcs Collaborators, Schleutker J, Wang Y, Pashayan N, Batra J, Apcb BioResource, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, Southey MC, Wolk A, Albanes D, Haiman CA, Travis RC, Stanford JL, Mucci LA, West CML, Nielsen SF et al. (2020)
The CHEK2 Variant C.349A>G Is Associated with Prostate Cancer Risk and Carriers Share a Common Ancestor
Cancers (Basel), 12 (11)
DOI 10.3390/cancers12113254, PubMed 33158149

Grindedal EM, Jørgensen K, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Vamre T, Wangensteen T, Heramb C, Mæhle L (2020)
Mainstreamed genetic testing of breast cancer patients in two hospitals in South Eastern Norway
Fam Cancer, 19 (2), 133-142
DOI 10.1007/s10689-020-00160-x, PubMed 32002722

Høberg-Vetti H, Ognedal E, Buisson A, Vamre TBA, Ariansen S, Hoover JM, Eide GE, Houge G, Fiskerstrand T, Haukanes BI, Bjorvatn C, Knappskog PM (2020)
The intronic BRCA1 c.5407-25T>A variant causing partly skipping of exon 23-a likely pathogenic variant with reduced penetrance?
Eur J Hum Genet, 28 (8), 1078-1086
DOI 10.1038/s41431-020-0612-1, PubMed 32203205

Wu L, Yang Y, Guo X, Shu XO, Cai Q, Shu X, Li B, Tao R, Wu C, Nikas JB, Sun Y, Zhu J, Roobol MJ, Giles GG, Brenner H, John EM, Clements J, Grindedal EM, Park JY, Stanford JL, Kote-Jarai Z, Haiman CA, Eeles RA, Zheng W, Long J, PRACTICAL consortium, CRUK Consortium, BPC3 Consortium, CAPS Consortium, PEGASUS Consortium (2020)
An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk
Nat Commun, 11 (1), 3905
DOI 10.1038/s41467-020-17673-9, PubMed 32764609

Publications 2019

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J et al. (2019)
Shared heritability and functional enrichment across six solid cancers
Nat Commun, 10 (1), 431
DOI 10.1038/s41467-018-08054-4, PubMed 30683880

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J et al. (2019)
Publisher Correction: Shared heritability and functional enrichment across six solid cancers
Nat Commun, 10 (1), 4386
DOI 10.1038/s41467-019-12095-8, PubMed 31548585

Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L et al. (2019)
Author Correction: Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Nat Commun, 10 (1), 382
DOI 10.1038/s41467-019-08293-z, PubMed 30655571

Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJS, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D et al. (2019)
Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
Eur Urol, 76 (6), 831-842
DOI 10.1016/j.eururo.2019.08.019, PubMed 31537406

Schumacher FR, Olama AAA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W et al. (2019)
Author Correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Nat Genet, 51 (2), 363
DOI 10.1038/s41588-018-0330-6, PubMed 30622367

Wangensteen T, Felde CN, Ahmed D, Mæhle L, Ariansen SL (2019)
Diagnostic mRNA splicing assay for variants in BRCA1 and BRCA2 identified two novel pathogenic splicing aberrations
Hered Cancer Clin Pract, 17, 14
DOI 10.1186/s13053-019-0113-9, PubMed 31143303

Wu L, Wang JF, Cai QY, Cavazos TB, Emami NC, Long JR, Shu XO, Lu YC, Guo XY, Bauer JA, Pasaniuc B, Penney KL, Freedman ML, Kote-Jarai Z, Witte JS, Haiman CA, Eeles RA, Zheng W, Benlloch S, Henderson BE, Conti DV, Schumacher FR, Easton D, Al Olama AA, Muir K, Berndt SI, Chanock S, Albanes D, Weinstein S, Koutros S et al. (2019)
Identification of Novel Susceptibility Loci and Genes for Prostate Cancer Risk: A Transcriptome-Wide Association Study in over 140,000 European Descendants
Cancer Res., 79 (13), 3192-3204
DOI 10.1158/0008-5472.CAN-18-3536

Publications 2018

Adams CD, Richmond R, Ferreira DLS, Spiller W, Tan V, Zheng J, Würtz P, Donovan J, Hamdy F, Neal D, Lane JA, Smith GD, Relton C, Eeles RA, Haiman CA, Kote-Jarai Z, Schumacher FR, Olama AAA, Benlloch S, Muir K, Berndt SI, Conti DV, Wiklund F, Chanock SJ, Gapstur S, Stevens VL, Tangen CM, Batra J, Clements JA, Gronberg H et al. (2018)
Circulating Metabolic Biomarkers of Screen-Detected Prostate Cancer in the ProtecT Study
Cancer Epidemiol Biomarkers Prev, 28 (1), 208-216
DOI 10.1158/1055-9965.EPI-18-0079, PubMed 30352818

Dadaev T, Saunders EJ, Newcombe PJ, Anokian E, Leongamornlert DA, Brook MN, Cieza-Borrella C, Mijuskovic M, Wakerell S, Olama AAA, Schumacher FR, Berndt SI, Benlloch S, Ahmed M, Goh C, Sheng X, Zhang Z, Muir K, Govindasami K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman P, Thompson IM, Batra J, Chambers S, Moya L, Clements J et al. (2018)
Fine-mapping of prostate cancer susceptibility loci in a large meta-analysis identifies candidate causal variants
Nat Commun, 9 (1), 2256
DOI 10.1038/s41467-018-04109-8, PubMed 29892050

Heramb C, Wangensteen T, Grindedal EM, Ariansen SL, Lothe S, Heimdal KR, Mæhle L (2018)
BRCA1 and BRCA2 mutation spectrum - an update on mutation distribution in a large cancer genetics clinic in Norway
Hered Cancer Clin Pract, 16, 3
DOI 10.1186/s13053-017-0085-6, PubMed 29339979

Kaikkonen E, Rantapero T, Zhang Q, Taimen P, Laitinen V, Kallajoki M, Jambulingam D, Ettala O, Knaapila J, Boström PJ, Wahlström G, Sipeky C, Pursiheimo JP, Tammela T, Kellokumpu-Lehtinen PL, PRACTICAL Consortium, Fey V, Maehle L, Wiklund F, Wei GH, Schleutker J (2018)
ANO7 is associated with aggressive prostate cancer
Int J Cancer, 143 (10), 2479-2487
DOI 10.1002/ijc.31746, PubMed 30157291

Lillestol K (2018)
Can the intestinal flora foresee effect of treatment?
Tidsskr. Nor. Laegeforen., 138 (7), 640

Lillestøl K (2018)
Kan tarmfloraen føreseie effekt av behandling?
Tidsskr Nor Laegeforen, 138 (7)
DOI 10.4045/tidsskr.18.0137, PubMed 29663788

Lillestøl K (2018)
'Neurasthenia gastrica' revisited: perceptions of nerve-gut interactions in nervous exhaustion, 1880-1920
Microb Ecol Health Dis, 29 (2), 1553438
DOI 10.1080/16512235.2018.1553438, PubMed 30651725

Matejcic M, Saunders EJ, Dadaev T, Brook MN, Wang K, Sheng X, Olama AAA, Schumacher FR, Ingles SA, Govindasami K, Benlloch S, Berndt SI, Albanes D, Koutros S, Muir K, Stevens VL, Gapstur SM, Tangen CM, Batra J, Clements J, Gronberg H, Pashayan N, Schleutker J, Wolk A, West C, Mucci L, Kraft P, Cancel-Tassin G, Sorensen KD, Maehle L et al. (2018)
Germline variation at 8q24 and prostate cancer risk in men of European ancestry
Nat Commun, 9 (1), 4616
DOI 10.1038/s41467-018-06863-1, PubMed 30397198

Mikropoulos C, Hutten Selkirk CG, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (6), e17
DOI 10.1038/bjc.2018.11, PubMed 29509747

Mikropoulos C, Selkirk CGH, Saya S, Bancroft E, Vertosick E, Dadaev T, Brendler C, Page E, Dias A, Evans DG, Rothwell J, Maehle L, Axcrona K, Richardson K, Eccles D, Jensen T, Osther PJ, van Asperen CJ, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Hart R, Glover W, Lam J, Taylor L, Salinas M, Feliubadaló L, Oldenburg R et al. (2018)
Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition
Br J Cancer, 118 (2), 266-276
DOI 10.1038/bjc.2017.429, PubMed 29301143

Norum J, Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Undlien DE, Schlichting E, Mæhle L (2018)
BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer
ESMO Open, 3 (3), e000328
DOI 10.1136/esmoopen-2018-000328, PubMed 29682331

Opsahl EM, Akslen LA, Schlichting E, Aas T, Brauckhoff K, Hagen AI, Rosenlund AF, Sigstad E, Grøholt KK, Mæhle L, Engebretsen LF, Jørgensen LH, Varhaug JE, Bjøro T (2018)
Trends in Diagnostics, Surgical Treatment, and Prognostic Factors for Outcomes in Medullary Thyroid Carcinoma in Norway: A Nationwide Population-Based Study
Eur Thyroid J, 8 (1), 31-40
DOI 10.1159/000493977, PubMed 30800639

Schumacher FR, Al Olama AA, Berndt SI, Benlloch S, Ahmed M, Saunders EJ, Dadaev T, Leongamornlert D, Anokian E, Cieza-Borrella C, Goh C, Brook MN, Sheng X, Fachal L, Dennis J, Tyrer J, Muir K, Lophatananon A, Stevens VL, Gapstur SM, Carter BD, Tangen CM, Goodman PJ, Thompson IM, Batra J, Chambers S, Moya L, Clements J, Horvath L, Tilley W et al. (2018)
Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci
Nat Genet, 50 (7), 928-936
DOI 10.1038/s41588-018-0142-8, PubMed 29892016

Singer CF, Balmaña J, Bürki N, Delaloge S, Filieri ME, Gerdes AM, Grindedal EM, Han S, Johansson O, Kaufman B, Krajc M, Loman N, Olah E, Paluch-Shimon S, Plavetic ND, Pohlodek K, Rhiem K, Teixeira M, Evans DG (2018)
Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations
Eur J Cancer, 106, 54-60
DOI 10.1016/j.ejca.2018.10.007, PubMed 30471648

Stormorken AT, Berg T, Norum OJ, Hølmebakk T, Aaberg K, Steigen SE, Grindedal EM (2018)
APC mosaicism in a young woman with desmoid type fibromatosis and familial adenomatous polyposis
Fam Cancer, 17 (4), 539-543
DOI 10.1007/s10689-018-0072-8, PubMed 29368261

Publications 2017

Chen H, Ewing CM, Zheng S, Grindedaal EM, Cooney KA, Wiley K, Djurovic S, Andreassen OA, Axcrona K, Mills IG, Xu J, Maehle L, Fosså SD, Isaacs WB (2017)
Genetic factors influencing prostate cancer risk in Norwegian men
Prostate, 78 (3), 186-192
DOI 10.1002/pros.23453, PubMed 29181843

Grindedal EM, Heramb C, Karsrud I, Ariansen SL, Mæhle L, Undlien DE, Norum J, Schlichting E (2017)
Current guidelines for BRCA testing of breast cancer patients are insufficient to detect all mutation carriers
BMC Cancer, 17 (1), 438
DOI 10.1186/s12885-017-3422-2, PubMed 28637432

Jarhelle E, Riise Stensland HM, Mæhle L, Van Ghelue M (2017)
Characterization of BRCA1 and BRCA2 variants found in a Norwegian breast or ovarian cancer cohort
Fam Cancer, 16 (1), 1-16
DOI 10.1007/s10689-016-9916-2, PubMed 27495310

Levin T, Mæhle L (2017)
Uptake of genetic counseling, genetic testing and surveillance in hereditary malignant melanoma (CDKN2A) in Norway
Fam Cancer, 16 (2), 257-265
DOI 10.1007/s10689-016-9939-8, PubMed 27804060

Sigstad E, Grøholt KK, Jørgensen K, Stormorken A, Li HS (2017)
A woman in her thirties with breast cancer and bilateral goitre
Tidsskr Nor Laegeforen, 137 (11), 806-809
DOI 10.4045/tidsskr.16.0577, PubMed 28597636

Publications 2016

Opsahl EM, Brauckhoff M, Schlichting E, Helset K, Svartberg J, Brauckhoff K, Mæhle L, Engebretsen LF, Sigstad E, Grøholt KK, Akslen LA, Jørgensen LH, Varhaug JE, Bjøro T (2016)
A Nationwide Study of Multiple Endocrine Neoplasia Type 2A in Norway: Predictive and Prognostic Factors for the Clinical Course of Medullary Thyroid Carcinoma
Thyroid, 26 (9), 1225-38
DOI 10.1089/thy.2015.0673, PubMed 27400880

Strand EB, Lillestol K, Jason LA, Tveito K, Diep LM, Valla SS, Sunnquist M, Helland IB, Herder I, Dammen T (2016)
Comparing the DePaul Symptom Questionnaire with physician assessments: a preliminary study
FATIGUE, 4 (1), 52-62
DOI 10.1080/21641846.2015.1126026

Publications 2015

Heramb C, Ekstrøm PO, Tharmaratnam K, Hovig E, Møller P, Mæhle L (2015)
Ten modifiers of BRCA1 penetrance validated in a Norwegian series
Hered Cancer Clin Pract, 13 (1), 14
DOI 10.1186/s13053-015-0035-0, PubMed 26052370

Parimalasingham BR, Bergan U, Jørgensen K (2015)
Fatty tissue in testicles
Tidsskr Nor Laegeforen, 135 (3), 242
DOI 10.4045/tidsskr.14.1262, PubMed 25668541

Szulkin R, Karlsson R, Whitington T, Aly M, Gronberg H, Eeles RA, Easton DF, Kote-Jarai Z, Al Olama AA, Benlloch S, Muir K, Giles GG, Southey MC, FitzGerald LM, Henderson BE, Schumacher FR, Haiman CA, Sipeky C, Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL, Hamdy FC, Pharoah PD, Pashayan N, Khaw KT, Stanford JL, Thibodeau SN et al. (2015)
Genome-wide association study of prostate cancer-specific survival
Cancer Epidemiol Biomarkers Prev, 24 (11), 1796-800
DOI 10.1158/1055-9965.EPI-15-0543, PubMed 26307654

Publications 2014

Bancroft EK, Page EC, Castro E, Lilja H, Vickers A, Sjoberg D, Assel M, Foster CS, Mitchell G, Drew K, Mæhle L, Axcrona K, Evans DG, Bulman B, Eccles D, McBride D, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Cybulski C, Wokolorczyk D, Selkirk C, Hulick PJ, Bojesen A, Skytte AB, Lam J, Taylor L, Oldenburg R, Cremers R et al. (2014)
Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study
Eur Urol, 66 (3), 489-99
DOI 10.1016/j.eururo.2014.01.003, PubMed 24484606

Finch AP, Lubinski J, Møller P, Singer CF, Karlan B, Senter L, Rosen B, Maehle L, Ghadirian P, Cybulski C, Huzarski T, Eisen A, Foulkes WD, Kim-Sing C, Ainsworth P, Tung N, Lynch HT, Neuhausen S, Metcalfe KA, Thompson I, Murphy J, Sun P, Narod SA (2014)
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation
J Clin Oncol, 32 (15), 1547-53
DOI 10.1200/JCO.2013.53.2820, PubMed 24567435

Grindedal EM, Aarset H, Bjørnevoll I, Røyset E, Mæhle L, Stormorken A, Heramb C, Medvik H, Møller P, Sjursen W (2014)
The Norwegian PMS2 founder mutation c.989-1G > T shows high penetrance of microsatellite instable cancers with normal immunohistochemistry
Hered Cancer Clin Pract, 12 (1), 12
DOI 10.1186/1897-4287-12-12, PubMed 24790682

Møller P, Stormorken A, Holmen MM, Hagen AI, Vabø A, Mæhle L (2014)
The clinical utility of genetic testing in breast cancer kindreds: a prospective study in families without a demonstrable BRCA mutation
Breast Cancer Res Treat, 144 (3), 607-14
DOI 10.1007/s10549-014-2902-1, PubMed 24619173

Publications 2013

Geisler J, Bachmann IM, Nyakas M, Helsing P, Fjøsne HE, Mæhle LO, Aamdal S, Eide NA, Svendsen HL, Straume O, Robsahm TE, Jacobsen KD, Akslen LA (2013)
Malignant melanoma--diagnosis, treatment and follow-up in Norway
Tidsskr Nor Laegeforen, 133 (20), 2154-9
DOI 10.4045/tidsskr.12.1416, PubMed 24172628

Hagen AI, Mæhle L, Vedå N, Vetti HH, Stormorken A, Ludvigsen T, Guntvedt B, Isern AE, Schlichting E, Kleppe G, Bofin A, Gullestad HP, Møller P (2013)
Risk reducing mastectomy, breast reconstruction and patient satisfaction in Norwegian BRCA1/2 mutation carriers
Breast, 23 (1), 38-43
DOI 10.1016/j.breast.2013.10.002, PubMed 24210736

Lillestøl K, Bondevik H (2013)
[Neurasthenia in Norway 1880-1920]
Tidsskr Nor Laegeforen, 133 (6), 661-5
DOI 10.4045/tidsskr.12.1221, PubMed 23552163

Møller P, Stormorken A, Jonsrud C, Holmen MM, Hagen AI, Clark N, Vabø A, Sun P, Narod SA, Mæhle L (2013)
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program
Breast Cancer Res Treat, 139 (1), 155-61
DOI 10.1007/s10549-013-2540-z, PubMed 23615785

Vasen HF, Blanco I, Aktan-Collan K, Gopie JP, Alonso A, Aretz S, Bernstein I, Bertario L, Burn J, Capella G, Colas C, Engel C, Frayling IM, Genuardi M, Heinimann K, Hes FJ, Hodgson SV, Karagiannis JA, Lalloo F, Lindblom A, Mecklin JP, Møller P, Myrhoj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Sijmons RH et al. (2013)
Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts
Gut, 62 (6), 812-23
DOI 10.1136/gutjnl-2012-304356, PubMed 23408351

Publications 2012

Bailey-Wilson JE, Childs EJ, Cropp CD, Schaid DJ, Xu J, Camp NJ, Cannon-Albright LA, Farnham JM, George A, Powell I, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Mæhle L, Møller P, Eeles R, Easton D, Guy M, Edwards S, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Stanford JL, Karyadi DM, Deutsch K et al. (2012)
Analysis of Xq27-28 linkage in the international consortium for prostate cancer genetics (ICPCG) families
BMC Med Genet, 13, 46
DOI 10.1186/1471-2350-13-46, PubMed 22712434

Møller P, Maehle L, Vabø A, Clark N, Sun P, Narod SA (2012)
Age-specific incidence rates for breast cancer in carriers of BRCA1 mutations from Norway
Clin Genet, 83 (1), 88-91
DOI 10.1111/j.1399-0004.2012.01855.x, PubMed 22320316

Publications 2011

Gregersen K, Valeur J, Lillestøl K, Frøyland L, Araujo P, Lied GA, Berstad A (2011)
Subjective food hypersensitivity: assessment of enterochromaffin cell markers in blood and gut lavage fluid
Int J Gen Med, 4, 555-60
DOI 10.2147/IJGM.S18349, PubMed 21887108

Lied GA, Lillestøl K, Lind R, Valeur J, Morken MH, Vaali K, Gregersen K, Florvaag E, Tangen T, Berstad A (2011)
Perceived food hypersensitivity: a review of 10 years of interdisciplinary research at a reference center
Scand J Gastroenterol, 46 (10), 1169-78
DOI 10.3109/00365521.2011.591428, PubMed 21679125

Lillestøl K, Schiøtz A (2011)
["Illegitimate children and the medical sciences"--quackery in Tidsskriftet 1990-24]
Tidsskr Nor Laegeforen, 131 (24), 2512-6
DOI 10.4045/tidsskr.11.1185, PubMed 22170145

Lu L, Cancel-Tassin G, Valeri A, Cussenot O, Lange EM, Cooney KA, Farnham JM, Camp NJ, Cannon-Albright LA, Tammela TL, Schleutker J, Hoegel J, Herkommer K, Maier C, Vogel W, Wiklund F, Emanuelsson M, Grönberg H, Wiley KE, Isaacs SD, Walsh PC, Helfand BT, Kan D, Catalona WJ, Stanford JL, FitzGerald LM, Johanneson B, Deutsch K, McIntosh L, Ostrander EA et al. (2011)
Chromosomes 4 and 8 implicated in a genome wide SNP linkage scan of 762 prostate cancer families collected by the ICPCG
Prostate, 72 (4), 410-26
DOI 10.1002/pros.21443, PubMed 21748754

Møller P, Clark N, Mæhle L (2011)
A SImplified method for Segregation Analysis (SISA) to determine penetrance and expression of a genetic variant in a family
Hum Mutat, 32 (5), 568-71
DOI 10.1002/humu.21441, PubMed 21309035

Publications 2010

Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV (2010)
Peutz-Jeghers syndrome: a systematic review and recommendations for management
Gut, 59 (7), 975-86
DOI 10.1136/gut.2009.198499, PubMed 20581245

Bodd TL, Van Ghelue M, Eiklid K, Ruud E, Møller P, Mæhle L (2010)
Fanconi anaemia, BRCA2 and familial considerations - follow up on a previous case report
Acta Paediatr, 99 (11), 1741-3
DOI 10.1111/j.1651-2227.2010.01929.x, PubMed 20608899

Christensen GB, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD, Walsh PC, Isaacs WB et al. (2010)
Genome-wide linkage analysis of 1,233 prostate cancer pedigrees from the International Consortium for Prostate Cancer Genetics using novel sumLINK and sumLOD analyses
Prostate, 70 (7), 735-44
DOI 10.1002/pros.21106, PubMed 20333727

Lied GA, Lillestøl K, Valeur J, Berstad A (2010)
Intestinal B cell-activating factor: an indicator of non-IgE-mediated hypersensitivity reactions to food?
Aliment Pharmacol Ther, 32 (1), 66-73
DOI 10.1111/j.1365-2036.2010.04314.x, PubMed 20353497

Lillestøl K, Helgeland L, Arslan Lied G, Florvaag E, Valeur J, Lind R, Berstad A (2010)
Indications of 'atopic bowel' in patients with self-reported food hypersensitivity
Aliment Pharmacol Ther, 31 (10), 1112-22
DOI 10.1111/j.1365-2036.2010.04261.x, PubMed 20163379

Lind R, Lied GA, Lillestøl K, Valeur J, Berstad A (2010)
Do psychological factors predict symptom severity in patients with subjective food hypersensitivity?
Scand J Gastroenterol, 45 (7-8), 835-43
DOI 10.3109/00365521003797213, PubMed 20433401

Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, Mitchell G, Lindeman GJ, Stapleton A, Suthers G, Evans DG, Cruger D, Blanco I, Mercer C, Kirk J, Maehle L, Hodgson S, Walker L, Izatt L, Douglas F, Tucker K, Dorkins H, Clowes V, Male A, Donaldson A, Brewer C, Doherty R, Bulman B, Osther PJ, Salinas M et al. (2010)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
BJU Int, 107 (1), 28-39
DOI 10.1111/j.1464-410X.2010.09648.x, PubMed 20840664

Møller P, Mæhle L, Engebretsen LF, Ludvigsen T, Jonsrud C, Apold J, Vabø A, Clark N (2010)
High penetrances of BRCA1 and BRCA2 mutations confirmed in a prospective series
Hered Cancer Clin Pract, 8 (1), 2
DOI 10.1186/1897-4287-8-2, PubMed 20180971

Sjursen W, Haukanes BI, Grindedal EM, Aarset H, Stormorken A, Engebretsen LF, Jonsrud C, Bjørnevoll I, Andresen PA, Ariansen S, Lavik LA, Gilde B, Bowitz-Lothe IM, Maehle L, Møller P (2010)
Current clinical criteria for Lynch syndrome are not sensitive enough to identify MSH6 mutation carriers
J Med Genet, 47 (9), 579-85
DOI 10.1136/jmg.2010.077677, PubMed 20587412

Publications 2009

Grindedal EM, Møller P, Eeles R, Stormorken AT, Bowitz-Lothe IM, Landrø SM, Clark N, Kvåle R, Shanley S, Maehle L (2009)
Germ-line mutations in mismatch repair genes associated with prostate cancer
Cancer Epidemiol Biomarkers Prev, 18 (9), 2460-7
DOI 10.1158/1055-9965.EPI-09-0058, PubMed 19723918

Grindedal EM, Renkonen-Sinisalo L, Vasen H, Evans G, Sala P, Blanco I, Gronwald J, Apold J, Eccles DM, Sánchez AA, Sampson J, Järvinen HJ, Bertario L, Crawford GC, Stormorken AT, Maehle L, Moller P (2009)
Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds
J Med Genet, 47 (2), 99-102
DOI 10.1136/jmg.2009.068130, PubMed 19635727

Hagen AI, Tretli S, Maehle L, Apold J, Vedå N, Møller P (2009)
Survival in Norwegian BRCA1 mutation carriers with breast cancer
Hered Cancer Clin Pract, 7 (1), 7
DOI 10.1186/1897-4287-7-7, PubMed 19366445

Lillestøl K, Berstad A, Lind R, Florvaag E, Arslan Lied G, Tangen T (2009)
Anxiety and depression in patients with self-reported food hypersensitivity
Gen Hosp Psychiatry, 32 (1), 42-8
DOI 10.1016/j.genhosppsych.2009.08.006, PubMed 20114127

Lind R, Lillestøl K, Valeur J, Eriksen HR, Tangen T, Berstad A, Arslan Lied G (2009)
Job stress and coping strategies in patients with subjective food hypersensitivity
Scand J Psychol, 51 (2), 179-84
DOI 10.1111/j.1467-9450.2009.00761.x, PubMed 19961557

Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bulow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Rahner N, Hes FJ, Hodgson S, Mecklin JP, Møller P, Myrhøj T, Nagengast FM, Parc Y, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen J, Lubinski J, Järvinen H et al. (2009)
Recommendations to improve identification of hereditary and familial colorectal cancer in Europe
Fam Cancer, 9 (2), 109-15
DOI 10.1007/s10689-009-9291-3, PubMed 19763885

Publications 2008

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE (2008)
CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer
PLoS One, 3 (8), e3062
DOI 10.1371/journal.pone.0003062, PubMed 18725978

Evans DG, Baildam AD, Anderson E, Brain A, Shenton A, Vasen HF, Eccles D, Lucassen A, Pichert G, Hamed H, Moller P, Maehle L, Morrison PJ, Stoppat-Lyonnet D, Gregory H, Smyth E, Niederacher D, Nestle-Krämling C, Campbell J, Hopwood P, Lalloo F, Howell A (2008)
Risk reducing mastectomy: outcomes in 10 European centres
J Med Genet, 46 (4), 254-8
DOI 10.1136/jmg.2008.062232, PubMed 18996907

Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, Steel M, Lalloo F, Apold J, Porteous ME, Vasen HF, van Asperen CJ, Moller P (2008)
Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers
J Med Genet, 46 (9), 593-7
DOI 10.1136/jmg.2008.058248, PubMed 18413372

Grindedal EM, Blanco I, Stormorken A, Maehle L, Clark N, González S, Capella G, Vasen H, Burn J, Møller P (2008)
High risk of endometrial cancer in colorectal cancer kindred is pathognomonic for MMR-mutation carriers
Fam Cancer, 8 (2), 145-51
DOI 10.1007/s10689-008-9219-3, PubMed 18841495

Helsing P, Nymoen DA, Ariansen S, Steine SJ, Maehle L, Aamdal S, Langmark F, Loeb M, Akslen LA, Molven A, Andresen PA (2008)
Population-based prevalence of CDKN2A and CDK4 mutations in patients with multiple primary melanomas
Genes Chromosomes Cancer, 47 (2), 175-84
DOI 10.1002/gcc.20518, PubMed 18023021

Maehle L, Apold J, Paulsen T, Hagen B, Løvslett K, Fiane B, Van Ghelue M, Clark N, Møller P (2008)
High risk for ovarian cancer in a prospective series is restricted to BRCA1/2 mutation carriers
Clin Cancer Res, 14 (22), 7569-73
DOI 10.1158/1078-0432.CCR-08-0112, PubMed 19010876

Norum J, Hagen AI, Maehle L, Apold J, Burn J, Møller P (2008)
Prophylactic bilateral salpingo-oophorectomy (PBSO) with or without prophylactic bilateral mastectomy (PBM) or no intervention in BRCA1 mutation carriers: a cost-effectiveness analysis
Eur J Cancer, 44 (7), 963-71
DOI 10.1016/j.ejca.2008.02.025, PubMed 18362067

Slipicevic A, Jørgensen K, Skrede M, Rosnes AK, Trøen G, Davidson B, Flørenes VA (2008)
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602

Vasen HF, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Järvinen H, Mecklin JP, Møller P, Myrhøi T, Nagengast FM, Parc Y, Phillips R, Clark SK, de Leon MP, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ et al. (2008)
Guidelines for the clinical management of familial adenomatous polyposis (FAP)
Gut, 57 (5), 704-13
DOI 10.1136/gut.2007.136127, PubMed 18194984

Publications 2007

Camp NJ, Cannon-Albright LA, Farnham JM, Baffoe-Bonnie AB, George A, Powell I, Bailey-Wilson JE, Carpten JD, Giles GG, Hopper JL, Severi G, English DR, Foulkes WD, Maehle L, Moller P, Eeles R, Easton D, Badzioch MD, Whittemore AS, Oakley-Girvan I, Hsieh CL, Dimitrov L, Xu J, Stanford JL, Johanneson B, Deutsch K, McIntosh L, Ostrander EA, Wiley KE, Isaacs SD et al. (2007)
Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics
Hum Mol Genet, 16 (11), 1271-8
DOI 10.1093/hmg/ddm075, PubMed 17478474

Hagen AI, Bofin AM, Ytterhus B, Maehle LO, Kjellevold KH, Myhre HO, Møller P, Lønning PE (2007)
Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations
Acta Oncol, 46 (2), 199-203
DOI 10.1080/02841860600949552, PubMed 17453369

Hagen AI, Kvistad KA, Maehle L, Holmen MM, Aase H, Styr B, Vabø A, Apold J, Skaane P, Møller P (2007)
Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series
Breast, 16 (4), 367-74
DOI 10.1016/j.breast.2007.01.006, PubMed 17317184

Moller P, Evans DG, Reis MM, Gregory H, Anderson E, Maehle L, Lalloo F, Howell A, Apold J, Clark N, Lucassen A, Steel CM (2007)
Surveillance for familial breast cancer: Differences in outcome according to BRCA mutation status
Int J Cancer, 121 (5), 1017-20
DOI 10.1002/ijc.22789, PubMed 17471561

Møller P, Hagen AI, Apold J, Maehle L, Clark N, Fiane B, Løvslett K, Hovig E, Vabø A (2007)
Genetic epidemiology of BRCA mutations--family history detects less than 50% of the mutation carriers
Eur J Cancer, 43 (11), 1713-7
DOI 10.1016/j.ejca.2007.04.023, PubMed 17574839

Møller P, Maehle L, Clark N, Apold J (2007)
No sib pair concordance for breast or ovarian cancer in BRCA1 mutation carriers
Hered Cancer Clin Pract, 5 (2), 67-71
DOI 10.1186/1897-4287-5-2-67, PubMed 19725986

Stormorken AT, Clark N, Grindedal E, Maehle L, Møller P (2007)
Prevention of colorectal cancer by colonoscopic surveillance in families with hereditary colorectal cancer
Scand J Gastroenterol, 42 (5), 611-7
DOI 10.1080/00365520601010230, PubMed 17454882

Vasen HF, Möslein G, Alonso A, Bernstein I, Bertario L, Blanco I, Burn J, Capella G, Engel C, Frayling I, Friedl W, Hes FJ, Hodgson S, Mecklin JP, Møller P, Nagengast F, Parc Y, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Wijnen J (2007)
Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer)
J Med Genet, 44 (6), 353-62
DOI 10.1136/jmg.2007.048991, PubMed 17327285

Publications 2006

Arslan G, Lillestøl K, Mulahasanovic A, Florvaag E, Berstad A (2006)
Food hypersensitivity reactions visualised by ultrasonography and magnetic resonance imaging in a patient lacking systemic food-specific IgE
Digestion, 73 (2-3), 111-5
DOI 10.1159/000094042, PubMed 16788291

Geirdal AØ, Maehle L, Heimdal K, Stormorken A, Møller P, Dahl AA (2006)
Quality of life and its relation to cancer-related stress in women of families with hereditary cancer without demonstrated mutation
Qual Life Res, 15 (3), 461-70
DOI 10.1007/s11136-005-3008-3, PubMed 16547785

Jørgensen K, Davidson B, Flørenes VA (2006)
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
Mod Pathol, 19 (11), 1446-55
DOI 10.1038/modpathol.3800662, PubMed 16951673

Møller P, Stormorken A, Apold J (2006)
[Handling of hereditary intestinal cancer]
Tidsskr Nor Laegeforen, 126 (15), 1937-9
PubMed 16915319

Rustad CF, Bjørnslett M, Heimdal KR, Mæhle L, Apold J, Møller P (2006)
Germline PTEN mutations are rare and highly penetrant
Hered Cancer Clin Pract, 4 (4), 177-85
DOI 10.1186/1897-4287-4-4-177, PubMed 20223021

Stormorken A, Heintz KM, Andresen PA, Hovig E, Møller P (2006)
MUTYH Mutations Do Not Cause HNPCC or Late Onset Familial Colorectal Cancer
Hered Cancer Clin Pract, 4 (2), 90-3
DOI 10.1186/1897-4287-4-2-90, PubMed 20223013

Stormorken AT, Hoff G, Norstein J, Bowitz-Lothe IM, Hanslien E, Grindedal E, Møller P (2006)
Estimated prevalence of hereditary cancers and the need for surveillance in a Norwegian county, Telemark
Scand J Gastroenterol, 41 (1), 71-9
DOI 10.1080/00365520510023891, PubMed 16373279

Vamre TB, Stalsberg H, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraceptives (2006)
Extra-tumoral breast tissue in breast cancer patients: variations with steroid contraceptive use
Int J Cancer, 118 (11), 2827-31
DOI 10.1002/ijc.21697, PubMed 16380999

Publications 2005

Geirdal AØ, Reichelt JG, Dahl AA, Heimdal K, Maehle L, Stormorken A, Møller P (2005)
Psychological distress in women at risk of hereditary breast/ovarian or HNPCC cancers in the absence of demonstrated mutations
Fam Cancer, 4 (2), 121-6
DOI 10.1007/s10689-004-7995-y, PubMed 15951962

Hope Q, Bullock S, Evans C, Meitz J, Hamel N, Edwards SM, Severi G, Dearnaley D, Jhavar S, Southgate C, Falconer A, Dowe A, Muir K, Houlston RS, Engert JC, Roquis D, Sinnett D, Simard J, Heimdal K, Møller P, Maehle L, Badzioch M, Eeles RA, Easton DF, English DR, Southey MC, Hopper JL, Foulkes WD, Giles GG, Cancer Research UK/British Association of Urological Surgeons' Section of Oncology Collaborators (2005)
Macrophage scavenger receptor 1 999C>T (R293X) mutation and risk of prostate cancer
Cancer Epidemiol Biomarkers Prev, 14 (2), 397-402
DOI 10.1158/1055-9965.EPI-04-0202, PubMed 15734964

Jørgensen K, Skrede M, Cruciani V, Mikalsen SO, Slipicevic A, Flørenes VA (2005)
Phorbol ester phorbol-12-myristate-13-acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2
Biochem Biophys Res Commun, 329 (1), 266-74
DOI 10.1016/j.bbrc.2005.01.143, PubMed 15721302

Møller P, Maehle L, Apold J (2005)
[Hereditary breast cancer]
Tidsskr Nor Laegeforen, 125 (22), 3136-8
PubMed 16299574

Stormorken AT, Bowitz-Lothe IM, Norèn T, Kure E, Aase S, Wijnen J, Apold J, Heimdal K, Møller P (2005)
Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer
J Clin Oncol, 23 (21), 4705-12
DOI 10.1200/JCO.2005.05.180, PubMed 16034045

Publications 2004

Flørenes VA, Skrede M, Jørgensen K, Nesland JM (2004)
Deacetylase inhibition in malignant melanomas: impact on cell cycle regulation and survival
Melanoma Res, 14 (3), 173-81
DOI 10.1097/01.cmr.0000129576.49313.26, PubMed 15179185

Hendriks YM, Wagner A, Morreau H, Menko F, Stormorken A, Quehenberger F, Sandkuijl L, Møller P, Genuardi M, Van Houwelingen H, Tops C, Van Puijenbroek M, Verkuijlen P, Kenter G, Van Mil A, Meijers-Heijboer H, Tan GB, Breuning MH, Fodde R, Wijnen JT, Bröcker-Vriends AH, Vasen H (2004)
Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance
Gastroenterology, 127 (1), 17-25
DOI 10.1053/j.gastro.2004.03.068, PubMed 15236168

Publications 2003

Heimdal K, Maehle L, Apold J, Pedersen JC, Møller P (2003)
The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer
Eur J Cancer, 39 (15), 2205-13
DOI 10.1016/s0959-8049(03)00548-3, PubMed 14522380

Jørgensen K, Holm R, Maelandsmo GM, Flørenes VA (2003)
Expression of activated extracellular signal-regulated kinases 1/2 in malignant melanomas: relationship with clinical outcome
Clin Cancer Res, 9 (14), 5325-31
PubMed 14614017

Stormorken AT, Müller W, Lindblom A, Heimdal K, Aase S, Lothe IM, Norèn T, Wijnen JT, Möslein G, Møller P (2003)
The inframe MSH2 codon 596 deletion is linked with HNPCC and associated with lack of MSH2 protein in tumours
Fam Cancer, 2 (1), 9-13
DOI 10.1023/a:1023362205205, PubMed 14574162

Publications 2002

Mollerup S, Jørgensen K, Berge G, Haugen A (2002)
Expression of estrogen receptors alpha and beta in human lung tissue and cell lines
Lung Cancer, 37 (2), 153-9
DOI 10.1016/s0169-5002(02)00039-9, PubMed 12140138

Møller P, Borg A, Evans DG, Haites N, Reis MM, Vasen H, Anderson E, Steel CM, Apold J, Goudie D, Howell A, Lalloo F, Maehle L, Gregory H, Heimdal K (2002)
Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy
Int J Cancer, 101 (6), 555-9
DOI 10.1002/ijc.10641, PubMed 12237897

Publications 2001

Møller P, Borg A, Heimdal K, Apold J, Vallon-Christersson J, Hovig E, Maehle L, Norwegian Inherited Breast Cancer Group, Norwegian Inherited Ovarian Cancer Group (2001)
The BRCA1 syndrome and other inherited breast or breast-ovarian cancers in a Norwegian prospective series
Eur J Cancer, 37 (8), 1027-32
DOI 10.1016/s0959-8049(01)00075-2, PubMed 11334729

Møller P, Heimdal K, Apold J, Fredriksen A, Borg A, Hovig E, Hagen A, Hagen B, Pedersen JC, Maehle L, Norwegian Inherited Breast Cancer Group, Norwegian Inherited Ovarian Cancer Group (2001)
Genetic epidemiology of BRCA1 mutations in Norway
Eur J Cancer, 37 (18), 2428-34
DOI 10.1016/s0959-8049(01)00299-4, PubMed 11720839

Stormorken AT, Müller W, Lemkemeyer B, Apold J, Wijnen JT, Fodde R, Möslein G, Møller P (2001)
Prediction of the outcome of genetic testing in HNPCC kindreds using the revised Amsterdam criteria and immunohistochemistry
Fam Cancer, 1 (3-4), 169-73
DOI 10.1023/a:1021151227983, PubMed 14574174

Vasen HF, Stormorken A, Menko FH, Nagengast FM, Kleibeuker JH, Griffioen G, Taal BG, Moller P, Wijnen JT (2001)
MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families
J Clin Oncol, 19 (20), 4074-80
DOI 10.1200/JCO.2001.19.20.4074, PubMed 11600610

Publications 2000

de Leeuw WJ, Dierssen J, Vasen HF, Wijnen JT, Kenter GG, Meijers-Heijboer H, Brocker-Vriends A, Stormorken A, Moller P, Menko F, Cornelisse CJ, Morreau H (2000)
Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients
J Pathol, 192 (3), 328-35
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH701>3.0.CO;2-2, PubMed 11054716

Møller P, Apold J, Maehle L, Heimdal K (2000)
[European guidelines for health care in hereditary breast cancer]
Tidsskr Nor Laegeforen, 120 (6), 726-7
PubMed 10806889

Publications 1999

Borg A, Dørum A, Heimdal K, Maehle L, Hovig E, Møller P (1999)
BRCA1 1675delA and 1135insA account for one third of Norwegian familial breast-ovarian cancer and are associated with later disease onset than less frequent mutations
Dis Markers, 15 (1-3), 79-84
DOI 10.1155/1999/278269, PubMed 10595257

Heimdal K, Apold J, Maehle L, Dørum A, Møller P (1999)
[Hereditary breast cancer in Norway]
Tidsskr Nor Laegeforen, 119 (26), 3929-32
PubMed 10592755

Heimdal K, Maehle L, Møller P (1999)
Costs and benefits of diagnosing familial breast cancer
Dis Markers, 15 (1-3), 167-73
DOI 10.1155/1999/751892, PubMed 10595273

Maehle L, Lystad E, Eilertsen E, Einarsdottír E, Høstmark AT, Haugen A (1999)
Growth of human lung adenocarcinoma in nude mice is influenced by various types of dietary fat and vitamin E
Anticancer Res, 19 (3A), 1649-55
PubMed 10470096

Moller P, Borg A, Evans G, Haites N, Steel CM, Vasen H, Gregory H, Hodgson S, Apold J, Lalloo F, Maehle L, Anderson E, Heimdal K, Biomed 2 Demonstration Programme I (1999)
Mutation-specific survival of inherited breast cancer
Dis. Markers, 15 (1-3), 205
DOI 10.1155/1999/902648

Moller P, Evans G, Anderson E, Maehle L, Lalloo F, Heimdal KR, Steel CM, Biomed 2 Demonstration Programme I (1999)
Use of cytology to diagnose inherited breast cancer
Dis. Markers, 15 (1-3), 206
DOI 10.1155/1999/909834

Møller P, Evans G, Haites N, Vasen H, Reis MM, Anderson E, Apold J, Hodgson S, Eccles D, Olsson H, Stoppa-Lyonnet D, Chang-Claude J, Morrison PJ, Bevilacqua G, Heimdal K, Maehle L, Lalloo F, Gregory H, Preece P, Borg A, Nevin NC, Caligo M, Steel CM (1999)
Guidelines for follow-up of women at high risk for inherited breast cancer: consensus statement from the Biomed 2 Demonstration Programme on Inherited Breast Cancer
Dis Markers, 15 (1-3), 207-11
DOI 10.1155/1999/920109, PubMed 10595280

Møller P, Reis MM, Evans G, Vasen H, Haites N, Anderson E, Steel CM, Apold J, Lalloo F, Maehle L, Preece P, Gregory H, Heimdal K (1999)
Efficacy of early diagnosis and treatment in women with a family history of breast cancer. European Familial Breast Cancer Collaborative Group
Dis Markers, 15 (1-3), 179-86
DOI 10.1155/1999/805420, PubMed 10595275

Stormorken AT, Apold J, Heimdal K, Møller P (1999)
[Hereditary colorectal cancer]
Tidsskr Nor Laegeforen, 119 (26), 3933-6
PubMed 10592756

Wijnen J, de Leeuw W, Vasen H, van der Klift H, Møller P, Stormorken A, Meijers-Heijboer H, Lindhout D, Menko F, Vossen S, Möslein G, Tops C, Bröcker-Vriends A, Wu Y, Hofstra R, Sijmons R, Cornelisse C, Morreau H, Fodde R (1999)
Familial endometrial cancer in female carriers of MSH6 germline mutations
Nat Genet, 23 (2), 142-4
DOI 10.1038/13773, PubMed 10508506

Publications 1998

Moller P, Maehle L, Heimdal K, Dorum A, Apold J, Engebretsen LF, Kaurin RM, Jorgensen OG, Helgerud P, Qvist H, Bjorndal H, Kullmann G, Bohler P, Nysted A, Soreide JA, Varhaug JE, Aas T, Fjosne HE, Hagen A, Due J, Karesen R, Formoe E, Malme PA, Stedjeberg JO, Svenningsen SS, Stenehjem E, Kolnes J, Verhage CCH, Haram S, Ronning GA et al. (1998)
Prospective findings in breast cancer kindreds: annual incidence rates according to age, stage at diagnosis, mean sojourn time, and incidence rates for contralateral cancer
Breast, 7 (1), 55-59
DOI 10.1016/S0960-9776(98)90053-4

Publications 1997

Dørum A, Møller P, Kamsteeg EJ, Scheffer H, Burton M, Heimdal KR, Maehle LO, Hovig E, Tropé CG, van der Hout AH, van der Meulen MA, Buys CH, te Meerman GJ (1997)
A BRCA1 founder mutation, identified with haplotype analysis, allowing genotype/phenotype determination and predictive testing
Eur J Cancer, 33 (14), 2390-2
DOI 10.1016/s0959-8049(97)00328-6, PubMed 9616287

Publications 1996

Mollerup S, Rivedal E, Mæhle L, Haugen A (1996)
Nickel(II) induces alterations in EGF- and TGF-beta 1-mediated growth control during malignant transformation of human kidney epithelial cells
Carcinogenesis, 17 (2), 361-7
DOI 10.1093/carcin/17.2.361, PubMed 8625464

Møller P, Maehle L, Heimdal K, Dørum A, Tretli S, Helgerud P, Quist H, Bjørndal H, Kåresen R, Nysted A, Varhaug JE, Fjøsne HE, Guleng RJ, Due J, Bøhler P, Giercksky KE, Tropé C, Kvinnsland S (1996)
Inherited breast carcinoma--prospective findings in 1,194 women at risk
Acta Oncol, 35 Suppl 8, 7-11
DOI 10.3109/02841869609098515, PubMed 9073043

Publications 1995

Maehle L, Eilertsen E, Mollerup S, Schønberg S, Krokan HE, Haugen A (1995)
Effects of n-3 fatty acids during neoplastic progression and comparison of in vitro and in vivo sensitivity of two human tumour cell lines
Br J Cancer, 71 (4), 691-6
DOI 10.1038/bjc.1995.136, PubMed 7710930

Publications 1994

Haugen A, Maehle L, Mollerup S, Rivedal E, Ryberg D (1994)
Nickel-induced alterations in human renal epithelial cells
Environ Health Perspect, 102 Suppl 3 (Suppl 3), 117-8
DOI 10.1289/ehp.94102s3117, PubMed 7843084

Publications 1992

Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC, Haugen A (1992)
Altered p53 gene structure and expression in human epithelial cells after exposure to nickel
Cancer Res, 52 (1), 218-21
PubMed 1727381